

## Special Issue

# Synaptic Function and Modulation in Health and Disease

### Message from the Guest Editor

Synaptic function and modulation are critical for proper nervous system function having been implicated in a myriad of processes ranging from basic neural communication to sophisticated behaviors and complex cognitive functions. Disruptions in synaptic mechanisms underlie a wide range of neurological and psychiatric disorders, highlighting it as a research area of the utmost importance to improve our understanding of these diseases and enable the development of more efficacious therapeutic strategies. This Special Issue aims to gather recent developments in our understanding of synaptic function and modulation, emphasizing its roles in health and disease. We encourage our colleagues to submit manuscripts on, but not limited to, the following topics: synaptic plasticity, neurotransmitter release, receptor dynamics, aging, and the impact of genetic and environmental factors on synaptic health. Computational studies are also welcome. By contributing to this Special Issue, authors will be able to share their research with a wide audience and thus foster collaboration and innovation in the field, thereby advancing our cumulative knowledge about this important topic.

### Guest Editor

Dr. Jean-Marie C. Bouteiller

Center for Neural Engineering & Institute for Technology and Medical Systems Innovation, Alfred E. Mann Department of Biomedical Engineering, Viterbi School of Engineering & Keck School of Medicine, University of Southern California, Los Angeles, CA 90007, USA

### Deadline for manuscript submissions

30 September 2025



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/216796](https://mdpi.com/si/216796)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).